期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
卷 1792, 期 9, 页码 841-843出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbadis.2008.11.012
关键词
Mannose supplementation; Heparin therapy; Congenital disorder of glycosylation; Hepatomegaly; PMI; Phosphomannose isomerase
资金
- Euroglycanet [LSHM-CT2005-512131]
- Fondation Jerome Lejeune
Phosphomannose isomerase (PMI) deficiency or congenital disorders of glycosylation type Ib (CDG Ib) is the only CDG that can be treated. Despite variable severity leading to dramatically different prognoses, clinical presentation is relatively homogeneous with liver and digestive features associated with hyperinsulinism and inconstant thrombosis. A feature of CDG is that coagulation factors are decreased. In our experience, mannose given orally at least 4 times per day not only transformed lethal CDG Ib into a treatable disease, but also improved the general condition and digestive symptoms of all reported patients but one. Liver disease. however, still persisted. Heparin can be used as an alternative to mannose in certain patients, particularly in the treatment of enteropathy. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据